Overview

Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blinded, placebo-controlled, crossover, single dose study in 24 pediatric patients (4-11 years old) with asthma. The entire study consists of (i) a Screening Visit and (ii) a Study Period with two (2) Study Visits. All study subjects must be properly consented, under adult supervision, and screened against the inclusion and exclusion criteria, at the Screening Visit.
Phase:
Phase 3
Details
Lead Sponsor:
Amphastar Pharmaceuticals, Inc.
Treatments:
Epinephrine
Epinephryl borate
Racepinephrine